Literature DB >> 3323644

Myoadenylate deaminase deficiency.

H H Goebel1, A Bardosi.   

Abstract

Myoadenylate deaminase (MAD) is the rate-limiting enzyme in the purine nucleotide cycle which is biochemically linked to glycolysis and the citric cycle and thereby providing energy during intense muscular activity. In muscle fibers, myoadenylate deaminase operates at considerably higher activity levels than in other organs. First detected using enzyme-histochemical methods, it now appears that deficiency of myoadenylate deaminase is one of the most frequent enzyme defects in muscle. The primary defect may occur as an isolated nosological entity or not infrequently it is also associated with a large spectrum of different neuromuscular conditions. It seems to be the primary unassociated MAD deficiency that has recently become amenable to successful treatment with D-ribose in high doses. Secondary MAD deficiency may occur in muscle fibers and muscles that have undergone structural damage as seen, for instance, in polymyositis, muscular dystrophy, and denervation. The wealth of biochemical, morphological, and clinical data that has accumulated since the discovery of MAD deficiency during the past decade provides nosological significance of MAD deficiency as a real entity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323644     DOI: 10.1007/BF01726321

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  50 in total

1.  The purine nucleotide cycle. Control of phosphofructokinase and glycolytic oscillations in muscle extracts.

Authors:  K Tornheim; J M Lowenstein
Journal:  J Biol Chem       Date:  1975-08-25       Impact factor: 5.157

2.  Muscle adenylic acid deaminase activity. Selective decrease in early-onset Duchenne muscular dystrophy.

Authors:  N C Kar; C M Pearson
Journal:  Neurology       Date:  1973-05       Impact factor: 9.910

3.  Increased ammonia production during forearm ischemic work test in McArdle's disease.

Authors:  K W Rumpf; H Wagner; H Kaiser; H M Meinck; H H Goebel; F Scheler
Journal:  Klin Wochenschr       Date:  1981-12-01

4.  Pathology of inflammatory and metabolic myopathies.

Authors:  V W Armbrustmacher; J L Griffin
Journal:  Pathol Annu       Date:  1981

5.  AMP deaminase: stage-specific isozymes in differentiating chick muscle.

Authors:  D W Sammons; O P Chilson
Journal:  Arch Biochem Biophys       Date:  1978-12       Impact factor: 4.013

6.  AMP deaminase activity of skeletal muscle in neuromuscular disorders in childhood. Histochemical and biochemical studies.

Authors:  H Nagao; S Habara; T Morimoto; N Sano; M Takahashi; K Kida; H Matsuda
Journal:  Neuropediatrics       Date:  1986-11       Impact factor: 1.947

7.  Exercising muscle does not produce hypoxanthine in adenylate deaminase deficiency.

Authors:  V H Patterson; K K Kaiser; M H Brooke
Journal:  Neurology       Date:  1983-06       Impact factor: 9.910

8.  Skeletal muscle adenosine, inosine and hypoxanthine release following ischaemic forearm exercise in myoadenylate deaminase deficiency and McArdle's disease.

Authors:  S Sinkeler; E Joosten; R Wevers; R Binkhorst; L Oei
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

9.  Differences in ammonia and adenylate metabolism in contracting fast and slow muscle.

Authors:  R A Meyer; R L Terjung
Journal:  Am J Physiol       Date:  1979-09

10.  Muscle adenylate deaminase deficiency. Report of six new cases.

Authors:  N C Kar; C M Pearson
Journal:  Arch Neurol       Date:  1981-05
View more
  7 in total

1.  Muscle metabolism and red cell ATP/ADP concentration during bicycle ergometer in patients with AMPD-deficiency.

Authors:  D R Wagner; J Felbel; U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-04-04

2.  Type 2a fibre rhabdomyolysis in myoadenylate deaminase deficiency.

Authors:  C Zimmer; H Altenkirch; S Dorfmüller-Küchlin; D Pongratz; I Paetzke; G Gosztonyi
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

Review 3.  Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency.

Authors:  M Gross
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

Review 4.  Molecular biology of AMP deaminase deficiency.

Authors:  M Gross
Journal:  Pharm World Sci       Date:  1994-04-15

5.  The oxidative pentose phosphate pathway in the heart: regulation, physiological significance, and clinical implications.

Authors:  H G Zimmer
Journal:  Basic Res Cardiol       Date:  1992 Jul-Aug       Impact factor: 17.165

6.  Myoadenylate deaminase deficiency with severe rhabdomyolysis.

Authors:  F A Baumeister; M Gross; D R Wagner; D Pongratz; R Eife
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

7.  Diagnostic Algorithm for Glycogenoses and Myoadenylate Deaminase Deficiency Based on Exercise Testing Parameters: A Prospective Study.

Authors:  Fabrice Rannou; Arnaud Uguen; Virginie Scotet; Cédric Le Maréchal; Odile Rigal; Pascale Marcorelles; Eric Gobin; Jean-Luc Carré; Fabien Zagnoli; Marie-Agnès Giroux-Metges
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.